{"id":113217,"title":"hVIVO PLC (AIM:HVO) Holding(s) in Company – JPMorgan Asset Management (UK) Limited","publisher":"Share Talk","author":"sharetalk","published":"2024-03-14T08:16:34+00:00","modified":"2024-03-14T08:20:23+00:00","canonical_url":"https://www.share-talk.com/hvivo-plc-aimhvo-holdings-in-company-jpmorgan-asset-management-uk-limited/","markdown_url":"https://www.share-talk.com/hvivo-plc-aimhvo-holdings-in-company-jpmorgan-asset-management-uk-limited.md","json_url":"https://www.share-talk.com/hvivo-plc-aimhvo-holdings-in-company-jpmorgan-asset-management-uk-limited.json","category":"Health","categories":["Health","Pharmaceutical"],"tags":["Andrew Catchpole","antiviral","breast cancer","Cathal Friel","CHIMagents","clinical respiratory drug","Codagenix","COVID-19","Dengue Fever","Dr Andrew Catchpole","Dr Chris Chiu","Gregory Stoloff","hVIVO","Imperial College London","Imutex Ltd","laboratory","Malaria","Open Orphan","ORPH","Oxford BioTherapeutics","pharmaceutical","quarantine clinic","Rahim Fandi","Share Talk","The Lancet","Vaccine","virology","West Nile Virus","Zika"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/12/HVO-WED-DEC-23.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"JP Morgan issued a new TR1 this morning bringing their shareholding to 6.9%, this is of course very positive news that such a large fund is heavily invested in hVIVO and supportive of the business and their story.\n\nTR-1: Standard form for notification of major holdings\n\n1. Issuer Details\n\nISIN\n\nGB00B9275X97\n\nIssuer Name\n\nhVIVO PLC\n\nUK or Non-UK Issuer\n\nUK\n\n2. Reason for Notification\n\nAn acquisition or disposal of voting rights\n\n3. Details of person subject to the notification obligation\n\nName\n\nJPMorgan Asset Management Holdings Inc.\n\nCity of registered office (if applicable)\n\nWilmington\n\nCountry of registered office (if applicable)\n\nUnited States of America\n\n4. Details of the shareholder\n\n|   |   |   |\n| --- | --- | --- |\n| Name | City of registered office | Country of registered office |\n| JPMorgan Asset Management (UK) Limited | London | United kingdom |\n\n5. Date on which the threshold was crossed or reached\n\n12-Mar-2024\n\n6. Date on which Issuer notified\n\n13-Mar-2024\n\n7. Total positions of person(s) subject to the notification obligation\n\n|   |   |   |   |   |\n| --- | --- | --- | --- | --- |\n|  | % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |\n| Resulting situation on the date on which threshold was crossed or reached | 5.048410% | 1.868195% | 6.916605% | 47,058,678 |\n| Position of previous notification (if applicable) | 3.215703% | 1.829392% | 5.045095% |  |\n\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n\n8A. Voting rights attached to shares\n\n|   |   |   |   |   |\n| --- | --- | --- | --- | --- |\n| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |\n| GB00B9275X97 |  | 34,347,989 |  | 5.048410% |\n| Sub Total 8.A | 34,347,989 | 5.048410% |  |  |\n\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\n\n|   |   |   |   |   |\n| --- | --- | --- | --- | --- |\n| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |\n|   |  |  |  |  |\n| Sub Total 8.B1 |  |  |  |  |\n\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\n\n|   |   |   |   |   |   |\n| --- | --- | --- | --- | --- | --- |\n| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |\n| Cash Settled – Equity Swaps | N/A | N/A | Cash | 12,710,689 | 1.868195% |\n| Sub Total 8.B2 |  | 12,710,689 | 1.868195% |  |  |\n\n9. Information in relation to the person subject to the notification obligation\n\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\n\n|   |   |   |   |   |\n| --- | --- | --- | --- | --- |\n| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |\n| JPMorgan Asset Management Holdings Inc. | JPMorgan Asset Management (UK) Limited |  |  | 6.804127% |\n| JPMorgan Asset Management Holdings Inc. | JPMorgan Asset Management (China) Company Limited |  |  |  |\n| JPMorgan Asset Management Holdings Inc. | JPMorgan Asset Management (Taiwan) Limited |  |  |  |\n\n10. In case of proxy voting\n\nName of the proxy holder\n\nThe number and % of voting rights held\n\nThe date until which the voting rights will be held\n\n11. Additional Information\n\nChain of controlled undertakings:\n\nJPMorgan Asset Management Holdings Inc\n\nJPMorgan Asset Management International Limited (100%)\n\nJPMorgan Asset Management (UK) Limited (100%)\n\nJPMorgan Asset Management Holdings Inc.\n\nJPMorgan Asset Management (China) Company Limited (100%)\n\nJPMorgan Asset Management Holdings Inc.\n\nJPMorgan Asset Management (Asia) Inc. (100%)\n\nJPMorgan Asset Management (Taiwan) Limited (100%)\n\n12. Date of Completion\n\n13-Mar-2024\n\n13. Place Of Completion\n\nHyderabad, India\n\n**About hVIVO**\n\n[hVIVO plc](http://www.hvivo.com/) (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.\n\nThe Group’s fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.\n\nhVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its [FluCamp](http://www.flucamp.com/) volunteer screening facilities in London and Manchester."}